These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 9450816)

  • 1. Allogeneic bone marrow transplantation for systemic AL amyloidosis.
    Gillmore JD; Davies J; Iqbal A; Madhoo S; Russell NH; Hawkins PN
    Br J Haematol; 1998 Jan; 100(1):226-8. PubMed ID: 9450816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogeneic bone marrow transplantation for AL amyloidosis.
    Guillaume B; Straetmans N; Jadoul M; Cosyns JP; Ferrant A
    Bone Marrow Transplant; 1997 Nov; 20(10):907-8. PubMed ID: 9404936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autologous transplantation for primary systemic AL amyloidosis is feasible outside a major amyloidosis referral centre: the Calgary BMT Program experience.
    Chow LQ; Bahlis N; Russell J; Chaudhry A; Morris D; Brown C; Stewart DA
    Bone Marrow Transplant; 2005 Oct; 36(7):591-6. PubMed ID: 16062177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced intensity allogeneic stem cell transplantation for systemic primary amyloidosis refractory to high-dose melphalan.
    Kawai Y; Kinoshita K; Arai H; Kuwata A; Fukuoka Y; Yamaoka M; Imamura S; Tsutani H; Ueda T
    Eur J Haematol; 2004 Jun; 72(6):448-50. PubMed ID: 15128426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Heart transplantation and the subsequent treatment of AL amyloidosis].
    Adam Z; Krejčí J; Krejčí M; Němec P; Spinarová L; Zampachová V; Cermáková Z; Pika T; Pour L; Kořístek Z; Tomíška M; Szturz P; Král Z; Mayer J
    Vnitr Lek; 2013 Feb; 59(2):136-47. PubMed ID: 23461404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose therapy in multiple myeloma and primary amyloidosis: an overview.
    Kyle RA
    Semin Oncol; 1999 Feb; 26(1):74-83. PubMed ID: 10073564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic and autologous bone marrow transplantation after consolidation therapy in high-risk acute myeloid leukemia in children. Towards a risk-oriented therapy.
    Ortega JJ; Díaz de Heredia C; Olivé T; Bastida P; Llort A; Armadans L; Torrabadella M; Massuet L
    Haematologica; 2003 Mar; 88(3):290-9. PubMed ID: 12651268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful reduced intensity allogeneic stem cell transplantation for systemic AL amyloidosis.
    Imamura T; Ogata M; Kohno K; Tomo T; Ohtsuka E; Kikuchi H; Kadota J
    Am J Hematol; 2006 Apr; 81(4):281-3. PubMed ID: 16550508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term successful outcome of sequential cardiac and allogeneic bone marrow transplantations in severe AL amyloidosis.
    Thaunat O; Alyanakian MA; Varnous S; Bors V; Damaj G; Rerolle JP; Jondeau K; Varet B; Gandjbakhch I; Buzyn A
    Bone Marrow Transplant; 2005 Feb; 35(4):419-20. PubMed ID: 15640825
    [No Abstract]   [Full Text] [Related]  

  • 10. No regression of renal AL amyloid in monoclonal gammopathy after successful autologous blood stem cell transplantation and significant clinical improvement.
    Zeier M; Perz J; Linke RP; Donini U; Waldherr R; Andrassy K; Ho AD; Goldschmidt H
    Nephrol Dial Transplant; 2003 Dec; 18(12):2644-7. PubMed ID: 14605290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The return of the normal heart: resolution of cardiac amyloidosis after chemotherapy and bone marrow transplantation.
    Fitzgerald BT; Bashford J; Scalia GM
    Heart Lung Circ; 2013 Aug; 22(8):655-60. PubMed ID: 23474152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current status of hematopoietic cell transplantation in the treatment of systemic amyloid light-chain amyloidosis.
    Schönland SO; Dreger P; de Witte T; Hegenbart U
    Bone Marrow Transplant; 2012 Jul; 47(7):895-905. PubMed ID: 21785469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolonged survival in mice with advanced tumors treated with syngeneic or allogeneic intra-bone marrow-bone marrow transplantation plus fetal thymus transplantation.
    Hosaka N; Cui W; Zhang Y; Takaki T; Inaba M; Ikehara S
    Cancer Immunol Immunother; 2010 Jul; 59(7):1121-30. PubMed ID: 20229083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current and emerging views and treatments of systemic immunoglobulin light-chain (Al) amyloidosis.
    Comenzo RL
    Contrib Nephrol; 2007; 153():195-210. PubMed ID: 17075231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Axoval neuropathy as initial manifestation of primary amyloidosis: report of a case submitted to bone marrow transplantation.
    Barsottini OG; Arantes A; Sigulem D; Kutner JM; Ribeiro AA; Moura LA; Hamerschlak N
    Arq Neuropsiquiatr; 2004 Sep; 62(3A):725-9. PubMed ID: 15334239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin's lymphoma.
    Aksentijevich I; Jones RJ; Ambinder RF; Garrett-Mayer E; Flinn IW
    Biol Blood Marrow Transplant; 2006 Sep; 12(9):965-72. PubMed ID: 16920563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring of human herpesviruses after allogeneic peripheral blood stem cell transplantation and bone marrow transplantation.
    Maeda Y; Teshima T; Yamada M; Shinagawa K; Nakao S; Ohno Y; Kojima K; Hara M; Nagafuji K; Hayashi S; Fukuda S; Sawada H; Matsue K; Takenaka K; Ishimaru F; Ikeda K; Niiya K; Harada M
    Br J Haematol; 1999 Apr; 105(1):295-302. PubMed ID: 10233397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on al amyloidosis-associated renal disease.
    Dember LM; Sanchorawala V; Seldin DC; Wright DG; LaValley M; Berk JL; Falk RH; Skinner M
    Ann Intern Med; 2001 May; 134(9 Pt 1):746-53. PubMed ID: 11329232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study.
    Skinner M; Sanchorawala V; Seldin DC; Dember LM; Falk RH; Berk JL; Anderson JJ; O'Hara C; Finn KT; Libbey CA; Wiesman J; Quillen K; Swan N; Wright DG
    Ann Intern Med; 2004 Jan; 140(2):85-93. PubMed ID: 14734330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of immature dendritic cells genetically modified to express sTNFR I on graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL) in allogeneic bone marrow transplantation mice].
    Wang SH; Li DP; Zhang YJ; Zhang P; Zeng LY; Pan XY; Xu KL; Huang YH
    Zhonghua Xue Ye Xue Za Zhi; 2012 Feb; 33(2):88-93. PubMed ID: 22730654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.